[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scn2a-dee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scn2a-dee":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100495944","phase-1-a-clinical-trial-of-prax-222-in-pediatric-participants-with-early-onset-scn2a-developmental-and-epileptic-encephalopathy-100495944",false,"NCT05737784","A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","Inclusion Criteria:\n\n* Has onset of seizures prior to 3 months of age.\n* Has a minimum weight of at least 10 kg at screening.\n* Has a documented SCN2A variant through genetic testing obtained via a laboratory accredited per Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) or equivalent.\n* Additional inclusion criteria apply and will be assessed by the study team\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and\u002For developmental disorder.\n* Is taking more than 2 sodium channel blocking anti-seizure medications\n* Additional exclusion criteria apply and will be assessed by the study team","ALL","2 Years","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.",[28,29],"SCN2A-DEE","Epilepsy",[31,32,33,34,35,36,37],"Antisense Oligonucleotide","NaV1.2 Voltage-Gated Sodium Channel","Voltage-Gated Sodium Channel Blockers","SCN2A variant","Pediatric epilepsy","Developmental and Epileptic Encephalopathy","DEE","RECRUITING","2025-08-15",{"date":41,"type":42},"2025-08-21","ACTUAL",{"date":44,"type":42},"2023-04-13",{"date":46,"type":21},"2027-09",{"name":48,"class":49},"Praxis Precision Medicines","INDUSTRY",3]